ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
antibody-based anticancer products, today announced that the following
presentations by Company management at upcoming investor conferences
will be webcast:
-
14th Annual BIO CEO & Investor Conference
3:00
pm on February 14, 2012 in New York, NY
Presenter: Daniel Junius,
President and CEO
-
2012 RBC Capital Markets' Healthcare Conference
1:30 pm on
February 29, 2012 in New York, NY
Presenter: Gregory Perry,
Executive Vice President and CFO
The webcast of each presentation can be accessed live through the
"Investor Information" section of the Company's website, www.immunogen.com;
a replay of each presentation will be available at the same location for
one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now numerous TAP compounds in
clinical development with a wealth of clinical data reported.
ImmunoGen's collaborative partners include Amgen, Bayer HealthCare
Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most
advanced compound using ImmunoGen's TAP technology, trastuzumab
emtansine (T-DM1), is in Phase III testing through the Company's
collaboration with Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations
and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media
Close window | Back to top
Delicious
Digg
Facebook
LinkedIn
Twitter
Mixx
Yahoo! Buzz